ARBs beyond blood pressure: few off-label benefits survive a credibility screen
- An umbrella review covered 15 systematic reviews and meta-analyses of randomised trials, spanning 35 non-traditional outcomes of angiotensin receptor blockers, appraised with AMSTAR 2 and GRADE.
- Nine outcomes were nominally significant, but only a few held up under stricter criteria: lower risk of headache and new-onset diabetes, and lower fasting insulin.
- Migraine severity, LDL cholesterol and insulin resistance were only suggestive; other outcomes lacked convincing support.
💡 Points Based on the abstract
Secondary outcomes from trials built for cardiovascular endpoints are hypothesis generation at best, and the prediction-interval check is the right sceptical filter. The diabetes signal is the one I'd take seriously, since renin–angiotensin blockade plausibly improves insulin sensitivity. The headache finding needs a dedicated migraine trial before anyone talks about repurposing.